Abstract
Syndrome of congestive heart failure is a clinical manifestation of many cardiac disease processes when the cardiovascular compensatory mechanisms are no longer able to maintain homeostasis. Approximately five million people in the United States have heart failure and over 550,000 of patients are diagnosed with heart failure for the first time each year. The Framingham heart study reported 62 and 42 % 5-year survival rates, respectively, for men and women with newly diagnosed congestive heart failure in the early 1970s. These mortality rates were six to seven times higher than that of age-matched general population. Of the total mortality, approximately 40–50 % were sudden deaths. The trending in the incidence and survival with heart failure among 11,311 subjects in the Framingham heart study during a 50-year interval has been updated. Heart failure occurred in 1,075 study participants between 1950 and 1999. The 5-year mortality rate among men declined from 70 % in the period from 1950 to 1969 to 59 % in the period from 1990 to 1999, whereas the respective rates among woman declined from 57 to 45 %. Although the relative declining of mortality is encouraging, likely a result of the better understanding of the disease patho-physiology and improvement of the medical and device therapy, the growing epidemics of heart failure has been increasingly recognized in the United States and around the globe.
The topic of heart failure and sudden death is enormously broad. Many specific and related topics are discussed in other chapters of the book. In this chapter, we will provide an overview on the following relevant issues: (1) mode of death in patients with heart failure; (2) arrhythmogenic substrates and triggers of malignant arrhythmias causing sudden death; (3) risk stratification schemes in identifying patients at increased risk of sudden death in heart failure; (4) outcomes from sudden death prevention clinical trials; and (5) a summary of current clinical management in sudden death prevention in heart failure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46(6):e1–82. Erratum in J Am Coll Cardiol. 2006 Apr 7;47(7):1503–1505.
McKee P. The natural history of congestive heart failure: the Framingham study. N Engl J Heart. 1971;285(26):1441–6.
Kannel W, Plehn J, Cupples L. Cardiac failure and sudden death in the Framingham study. Am Heart J. 1988;115(4):869–75.
Levy D et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402.
Luu M et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675–80.
Cha YM, Shen WK. Heart failure and sudden death. In: Gussak I, Antzelevitch C, editors. Electrical Diseases of the Heart. Springer Publishers; 2008. pp. 874.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.
Mitchel L et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol. 2002;39(8):1323–8.
Hunt SA. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46(6):e1-82.
Hunt S et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–235.
Cubbon RM et al. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction/clinical perspective. Circ Heart Fail. 2011;4(4):396–403.
Nabauer M, Barth A, Kaab S. A second calcium-independent transient outward current present in human left ventricular myocardium. Circulation. 1998;98(1):231.
Priebe L, Beuckelmann D. Stimulation study of cellular electric properties in heart failure. Circ Res. 1998;82(11):1206–23.
Tsui Y, Opthof T, Kamiya K. Pacing-induced heart failure causes a reduction of delayed rectifier potassium current along with decreases in calcium and transient outward currents in rabbit ventricle. Cardiovasc Res. 2000;48:300–9.
Beuckelmann D. Ca(2+)-currents and intracellular (Ca2+)i-transients in single ventricular myocytes isolated from terminally failing human myocardium. Basic Res Cardiol. 1992;87(1):235–43.
Mews T, Ravens U. L-type calcium currents of human myocytes from ventricle of non-failing hearts and from atrium. J Mol Cell Cardiol. 1994;26:1307–20.
Mukherjee R et al. Changes in L-type calcium channel abundance and function during the transition to pacing-induced congestive heart failure. Cardiovasc Res. 1998;37:432–44.
Bers D, Eisner D, Valdivia H. Sarcoplasmic reticulum CA2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ Res. 2003;93:487–90.
Vermeulen J, McGuire M, Opthof T. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts. Cardiovasc Res. 1994;28:1547–54.
Poelzing S, Rosenbaum D. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am J Physiol. 2004;287:H1762–70.
Guth L. Regeneration in the mammalian peripheral nervous system. Physiol Rev. 1956;36:441–78.
Meiri K. Growth-associated protein, GAP-43, a polypeptide that is induced when neurons extend axons, is a component of growth cones and corresponds to pp 46, a major polypeptide of a subcellular fraction enriched in growth cones. Proc Natl Acad Sci USA. 1986;83(10):3537–41.
Oh Y et al. Spatial distribution of nerve sprouting after myocardial infarction in mice. Heart J. 2006;3(6):728–36.
Zhou S. Mechanisms of cardiac nerve sprouting after myocardial infarction in dogs. Circ Res. 2004;95:76–83.
Chen LS, Zhou S, Fishbein MC, et al. New perspectives on the role of autonomic nervous system in the genesis of arrhythmias. J Cardiovasc Electrophysiol. 2006;17:1–5.
Cao J. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation. 2000;101:1960–9.
Cao J. Nerve sprouting and sudden cardiac death. Circ Res. 2000;86:816–21.
Cha Y. Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure. Heart Rhythm. 2005;2(9):984–90.
Jardine D. A neural mechanism for sudden death after myocardial infarction. Clin Auton Res. 2003;13:339–41.
Schwartz P, Priori S. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. Philadelphia: W.B. Saunders Company; 1990. p. 330–43.
de Bakker J et al. Slow conduction in the infarcted human heart ‘Zigzag’ course of activation. Circulation. 1993;88:915–26.
Stevenson W et al. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation. 1993;88:1647–60.
Gardner P. Electrophysiologic and anatomic basis for fractionated electrograms recorded from healed myocardial. Circulation. 1985;72:596–611.
Brembilla-Perrot B, Houriez P, Claudon O. Long-term reproducibility of ventricular tachycardia induction with electrophysiological testing in patients with coronary artery disease and depressed left ventricular ejection fraction. PACE. 2000;23:47–53.
de Bakker JM et al. Fractionated electrograms in dilated cardiomyopathy: origin and relation to abnormal conduction. J Am Coll Cardiol. 1996;27(5):1071–8.
Caceres J. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989;79:256–70.
Cooper H. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–5.
Gettes L. Electrolyte abnormalities underlying lethal ventricular arrhythmias. Circulation. 1992;85:70–6.
Reiter M et al. Electrophysiological effects of acute dilatation in the isolated rabbit heart: cycle length-dependent effects on ventricular refractoriness and conduction velocity. Circulation. 1997;96:4050–6.
Dean J, Lab M. Arrhythmia in heart failure: role of mechanically induced changes in electrophysiology. Lancet. 1989;1:1309.
Koilpillai C, Quinones MA, Greenberg B, et al. Relation of ventricular size and function to heart failure status and ventricular dysrhythmia in patients with severe left ventricular dysfunction. Am J Cardiol. 1996;77:606–11.
Wu J, Zipes D. Transmural reentry during global acute ischemia and reperfusion in canine ventricular muscle. Am J Physiol. 2001;280:H2717–25.
Buxton A et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341(25):1882–90.
Moss A et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.
Solomon S et al. Effect of Candesartan on cause-specific mortality in heart failure patients. Circulation. 2004;110:2180–3.
Brendorp B et al. QT dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. Circulation. 2001;103:831–5.
Brooksby P et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. Eur Heart J. 1999;20:1335–41.
Kitamura H et al. Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2002;39(2):295–300.
Bloomfield D et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy. Circulation. 2004;110:1885–9.
Doust J et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J. 2005;330:1–9.
Klingenheben T et al. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. Lancet. 2000;356(9230):651–2.
Woo M, Stevenson W, Moser D. Complex heart rate variability and serum norepinephrine levels in patients with advanced heart failure. J Mol Cell Cardiol. 1994;23:565–9.
La Rovere M et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation. 2003;107:565–70.
Yamada T et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41(2):231–8.
Berger R, Huelsmann M, Streckes K. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur J Clin Invest. 2005;35(1):24–31.
Waagstein F et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37(10):1022–36.
Hjalmarson A et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA. 2000;283(10):1295–302.
Packer M et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.
Investigators C. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.
Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–67.
Poole-Wilson P et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13.
Ellison K et al. Effect of B-blocking therapy on outcome in the multicenter unsustained tachycardia trial (MUSTT). Circulation. 2002;106:2694–9.
Pfeffer M et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759–66.
Granger C et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–6.
McMurray J et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767–71.
Vusuf S et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777–81.
St. John Sutton M et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577–82.
Domanski M, Exner D, Borkowf C. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. J Mol Cell Cardiol. 1999;33:598.
Doval H et al. Lancet. 1994;344(8921):493–8.
Singh S, Fletcher R, Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77–82.
Bardy G et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.
Poole-Wilson P et al. Mode of death in heart failure: findings from the ATLAS trial. Heart J. 2003;89(1):42–8.
Massie B et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 1996;93(12):2128–34.
Cairns J et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 1997;349(9053):675–82.
Julian D et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 1997;349(9053):667–74.
Torp-Pedersen C. Classification of sudden and arrhythmia death. Pacing Clin Electrophysiol. 1997;20:2545–52.
Echt D et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. JAMA. 1991;324(12):781–8.
Teo K, Usuf S, Furberg C. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA. 1993;270:1589–95.
Investigators A. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576–84.
Kuck K et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748–54.
Connolly S et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297–302.
Knight B, Goyal R, Pelosi F. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol. 1999;33(7):1964–70.
Moss A. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–40.
Packer DL et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure. Circulation. 2009;120(22):2170–6.
Moss A et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Heart. 1996;335(26):1933–40.
Bigger J, Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Heart. 1997;337(22):1569–75.
Hohnloser S et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481–8.
Kadish A et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151–8.
Bradley D et al. Cardiac resynchronization and death from progressive heart failure: a metaanalysis of randomized controlled trials. JAMA. 2003;289:730–40.
Bristow M et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.
Cleland J et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
Moss AJ et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.
Zareba W et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT)/Clinical Perspective. Circulation. 2011;123(10):1061–72.
Poole JE et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359(10):1009–17.
Reddy VY et al. Short-term results of substrate mapping and radiofrequency ablation of ischemic ventricular tachycardia using a saline-irrigated catheter. J Am Coll Cardiol. 2003;41(12):2228–36.
Calkins H et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol. 2000;35(7):1905–14.
Stevenson WG et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction. Circulation. 2008;118(25):2773–82.
Carbucicchio C et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-defibrillators. Circulation. 2008;117(4):462–9.
Kuck K-H et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2013;375(9708):31–40.
Reddy VY et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357(26):2657–65.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Cha, YM., Shen, WK. (2013). Heart Failure and Sudden Death. In: Gussak, I., Antzelevitch, C. (eds) Electrical Diseases of the Heart. Springer, London. https://doi.org/10.1007/978-1-4471-4978-1_25
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4978-1_25
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4977-4
Online ISBN: 978-1-4471-4978-1
eBook Packages: MedicineMedicine (R0)